Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference107 articles.
1. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients;Cibeira;Blood,2011
2. A new staging system for cardiac transthyretin amyloidosis;Gillmore;Eur Heart J,2017
3. Evolving landscape in the management of transthyretin amyloidosis;Hawkins;Ann Med,2015
4. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis;Maurer;Circulation,2017
5. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction;Mohammed;J Am Coll Cardiol HF,2014
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy;Heart Failure Reviews;2024-01-18
2. Emerging therapeutic avenues in cardiac amyloidosis;European Journal of Pharmacology;2023-12
3. Conformational inhibitors of protein aggregation;Current Opinion in Structural Biology;2023-12
4. Recent Progress in the Development and Clinical Application of New Drugs for Transthyretin Cardiac Amyloidosis;Journal of Cardiovascular Pharmacology;2023-11-30
5. Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus;Expert Review of Pharmacoeconomics & Outcomes Research;2023-02-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3